Reni J. Benjamin
Stock Analyst at Citizens
(3.76)
# 3,478
Out of 5,182 analysts
27
Total ratings
45.83%
Success rate
13.26%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Reni J. Benjamin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CMPX Compass Therapeutics | Reiterates: Market Outperform | $10 | $1.91 | +423.56% | 1 | Apr 28, 2026 | |
| STRO Sutro Biopharma | Maintains: Market Outperform | $35 → $41 | - | - | 2 | Apr 23, 2026 | |
| WHWK Whitehawk Therapeutics | Initiates: Market Outperform | $8 | - | - | 1 | Apr 16, 2026 | |
| ALLO Allogene Therapeutics | Maintains: Market Outperform | $5 → $8 | $2.29 | +249.34% | 1 | Apr 14, 2026 | |
| BCAX Bicara Therapeutics | Reiterates: Market Outperform | $31 | $22.66 | +36.80% | 2 | Mar 31, 2026 | |
| IMMX Immix Biopharma | Reiterates: Market Outperform | $23 | $9.57 | +140.33% | 1 | Mar 27, 2026 | |
| LYEL Lyell Immunopharma | Initiates: Market Outperform | $34 | $23.10 | +47.19% | 1 | Mar 9, 2026 | |
| IOVA Iovance Biotherapeutics | Upgrades: Market Outperform | $5 | $3.45 | +44.93% | 2 | Mar 3, 2026 | |
| IMMP Immutep | Initiates: Market Outperform | $10 | $0.48 | +2,005.26% | 2 | Feb 23, 2026 | |
| SMMT Summit Therapeutics | Reiterates: Market Outperform | $40 | $22.23 | +79.94% | 4 | Jan 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Outperform | $32 | $28.70 | +11.50% | 1 | Dec 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $348 → $396 | $299.26 | +32.33% | 1 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $5 → $8 | $3.37 | +137.39% | 1 | Oct 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $24 | $9.13 | +163.01% | 2 | Oct 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Perform | n/a | $129.20 | - | 1 | Aug 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $4 → $3 | $0.80 | +275.00% | 1 | Aug 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $4 → $3 | $4.65 | -35.48% | 1 | Aug 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $4.75 | - | 1 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $22 → $10 | $4.79 | +108.77% | 1 | Aug 12, 2025 |
Compass Therapeutics
Apr 28, 2026
Reiterates: Market Outperform
Price Target: $10
Current: $1.91
Upside: +423.56%
Sutro Biopharma
Apr 23, 2026
Maintains: Market Outperform
Price Target: $35 → $41
Current: -
Upside: -
Whitehawk Therapeutics
Apr 16, 2026
Initiates: Market Outperform
Price Target: $8
Current: -
Upside: -
Allogene Therapeutics
Apr 14, 2026
Maintains: Market Outperform
Price Target: $5 → $8
Current: $2.29
Upside: +249.34%
Bicara Therapeutics
Mar 31, 2026
Reiterates: Market Outperform
Price Target: $31
Current: $22.66
Upside: +36.80%
Immix Biopharma
Mar 27, 2026
Reiterates: Market Outperform
Price Target: $23
Current: $9.57
Upside: +140.33%
Lyell Immunopharma
Mar 9, 2026
Initiates: Market Outperform
Price Target: $34
Current: $23.10
Upside: +47.19%
Iovance Biotherapeutics
Mar 3, 2026
Upgrades: Market Outperform
Price Target: $5
Current: $3.45
Upside: +44.93%
Immutep
Feb 23, 2026
Initiates: Market Outperform
Price Target: $10
Current: $0.48
Upside: +2,005.26%
Summit Therapeutics
Jan 30, 2026
Reiterates: Market Outperform
Price Target: $40
Current: $22.23
Upside: +79.94%
Dec 3, 2025
Initiates: Market Outperform
Price Target: $32
Current: $28.70
Upside: +11.50%
Nov 7, 2025
Maintains: Market Outperform
Price Target: $348 → $396
Current: $299.26
Upside: +32.33%
Oct 30, 2025
Maintains: Market Outperform
Price Target: $5 → $8
Current: $3.37
Upside: +137.39%
Oct 20, 2025
Reiterates: Market Outperform
Price Target: $24
Current: $9.13
Upside: +163.01%
Aug 22, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $129.20
Upside: -
Aug 21, 2025
Maintains: Market Outperform
Price Target: $4 → $3
Current: $0.80
Upside: +275.00%
Aug 18, 2025
Maintains: Market Outperform
Price Target: $4 → $3
Current: $4.65
Upside: -35.48%
Aug 13, 2025
Downgrades: Market Perform
Price Target: n/a
Current: $4.75
Upside: -
Aug 12, 2025
Maintains: Market Outperform
Price Target: $22 → $10
Current: $4.79
Upside: +108.77%